Atlas Venture Life Science Advisors

Atlas Venture Life Science Advisors as of June 30, 2022

Portfolio Holdings for Atlas Venture Life Science Advisors

Atlas Venture Life Science Advisors holds 16 positions in its portfolio as reported in the June 2022 quarterly 13F filing

Company (Ticker) Portfolio Weight Valued At Change in Shares Share Count Share Price
Day One Biopharmaceuticals Common Stock (DAWN) 26.8 $161M 9.0M 17.90
Kymera Therapeutics Common Stock (KYMR) 22.6 $135M 6.9M 19.69
Dyne Therapeutics Common Stock (DYN) 10.3 $61M 8.9M 6.87
Replimune Group Common Stock (REPL) 9.4 $56M 3.2M 17.48
Generation Bio Common Stock (GBIO) 9.1 $54M 8.3M 6.56
Aerovate Therapeutics Common Stock (AVTE) 6.9 $41M 2.6M 15.63
Ikena Oncology Common Stock (IKNA) 3.7 $22M 5.0M 4.43
Akero Therapeutics Common Stock (AKRO) 3.5 $21M 2.2M 9.45
Vigil Neuroscience Common Stock (VIGL) 2.5 $15M 5.8M 2.58
Gemini Therapeutics Common Stock 1.5 $8.9M 5.3M 1.69
Xilio Therapeutics Common Stock (XLO) 1.3 $8.1M 2.8M 2.92
Magenta Therapeutics Common Stock 0.7 $4.2M 3.5M 1.20
AvroBio Common Stock (AVRO) 0.7 $4.2M 4.5M 0.92
F-star Therapeutics Common Stock 0.6 $3.8M 600k 6.26
Viridian Therapeutics Common Stock (VRDN) 0.2 $1.0M 90k 11.57
Spero Therapeutics Common Stock (SPRO) 0.1 $764k 1.0M 0.74